Background

Prof. Gert Riethmüller, Ph.D. has been the Head of the Tumor Center of Munich at the Institute of University since 1979. Prof. Riethmüller co-founded Micromet, inc. in August 1996 and served as its Scientific Advisor and Member of the Supervisory Board. He is highly recognized internationally for the development of monoclonal antibodies and their everyday clinical use, for example, in rheumatoid arthritis and other auto-immune diseases. He has made a decisive contribution ... to immune therapy and especially to the antibody therapy of cancer diseases. He serves as a Professor of University of Munich, Germany. He qualified as a University Lecturer at Tübingen University in 1971, where he became the Head of the Immunology and Experimental Surgery Department. In 1977, he became a Professor for Immunology of Ludwig Maximilian University in Munich, of which he is the Director. He is on the Executive Board of the Institute for Immunology of Ludwig Maximilian University, Munich. He is a Member of the Advisory Boards of numerous domestic and foreign research centers, foundations, and institutes. He serves as a Member of the Scientific Advisory Council at Cancer Research Institute, Inc. He served as a Member of Scientific Advisory Board at Heidelberg Innovation BioScience Venture II GmbH & Co. KG, L.P. and Heidelberg Innovation Gruppe. He received the following awards including the Gerhard-Domagk prize for Cancer Research, the Meyenburg prize of the Deutsches Krebsforschungszentrum (German Cancer Research Center) in Heidelberg and the Honorary Doctorate of the medical faculty of Greifswald University and of Hannover Medical College. Prof. Riethmüller has studied Medicine and spent a Post-Doctoral period at well-known universities in Europe and America. He holds a Doctorate degree.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.